Enbrel is indicated for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a tumor necrosis factor (TNF) blocker. Etanercept is the active ingredient. It is supplied as a solution for injection. This product was originally manufactured by Immunex Corporation. Currently, this product is manufactured by Amgen Inc. due to the acquisition of Immunex by Amgen.
What is it made of?
Enbrel is a clear and colorless, sterile, preservative-free solution. Enbrel’s active ingredient is etanercept. It is a TNF blocker which is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the tumor necrosis factor receptor. Enbrel is produced by recombinant deoxyribonucleic acid (DNA) technology.
What are its uses?
Enbrel helps treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Enbrel can reduce disease signs and symptoms, induce major clinical response, inhibit progression of structural damage, and improve physical function in patients.
How long do its effects last?
Studies show the half-life of Enbrel to be approximately 102 hours and clearance to be approximately 160ml/hr for rheumatoid arthritis patients administered a single injection of 25mg. Furthermore, it has been observed that serum concentration profiles at steady-state were comparable among patients treated with 50mg once weekly and those treated with 25mg twice weekly.